You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
藥明合聯(02268.HK)擬折價配股募資13億港元 加速生物偶聯藥物等產能佈局
格隆匯 09-03 06:44

格隆匯9月3日丨藥明合聯(02268.HK)發佈公吿,2025年9月2日,公司與配售代理(即摩根士丹利)訂立配售協議,據此,公司已有條件同意透過配售代理按悉數包銷基準按配售價每股配售股份58.85港元向不少於六名承配人配售最多2227.7萬股配售股份。配售股份將根據一般授權發行及配發。

配售事項項下的配售股份最高數目佔(i)於本公吿日期公司現有已發行股本約1.85%;及(ii)經發行及配發配售股份擴大後的已發行股本約1.82%。配售價每股配售股份58.85港元較於最後交易日於聯交所所報收市價每股股份61.30港元折讓約4.00%。

假設配售股份獲悉數配售,配售事項預期的所得款項總額將為13.11億港元(相當於約1.68億美元),配售事項的所得款項淨額將約為13.01億港元(相當於約1.67億美元)。公司擬將配售事項所得款項淨額總額按以下方式運用:(i)約90%將用於進一步擴大集團的服務能力及產能,包括但不限於其生物偶聯藥物、原料藥及產品的臨牀及商業生產產能;(ii)約10%將用於集團的營運資金需求及一般公司用途。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account